Tocilizumab
- Generic Name
- Tocilizumab
- Brand Names
- Actemra, RoActemra, Tyenne, Tofidence
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 375823-41-9
- Unique Ingredient Identifier
- I031V2H011
- Background
Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflamm...
- Indication
Tocilizumab is indicated to treat moderate to severe rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.
...
- Associated Conditions
- Coronavirus Disease 2019 (COVID‑19), Cytokine Release Syndrome caused by CAR-T Cell Therapy, Giant Cell Arteritis (GCA), Juvenile Chronic Polyarthritis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis (SJIA), Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), Active systemic Juvenile idiopathic arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- Monotherapy
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 75
- Registration Number
- NCT05972135
- Locations
- 🇺🇸
Texas Oncology, Austin, Texas, United States
🇺🇸Arizona Oncology Associates, Tucson, Arizona, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
- Conditions
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05927571
- Locations
- 🇮🇱
Tel Aviv Sourasky Medical Center PPDS, Tel Aviv-Yafo, Israel
🇮🇱Sheba Medical Center - PPDS, Ramat Gan, Israel
🇦🇺The Alfred Hospital, Prahan, Victoria, Australia
LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Lebanese University
- Target Recruit Count
- 1000
- Registration Number
- NCT05925140
- Locations
- 🇱🇧
Lebanese University, Tripoli, Lebanon
🇱🇧SZUMC, Zgharta, North, Lebanon
"Comparison of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Severe Uveitis of Behçet's Disease"
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 60
- Registration Number
- NCT05874505
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases
- Conditions
- Interventions
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2024-12-19
- Target Recruit Count
- 129
- Registration Number
- NCT05869955
- Locations
- 🇪🇸
Hospital Universitario Reina Sofia, Cordoba, Spain
🇺🇸University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients
- First Posted Date
- 2023-05-11
- Last Posted Date
- 2023-06-02
- Target Recruit Count
- 48
- Registration Number
- NCT05855122
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers
- Conditions
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Kathy Miller
- Target Recruit Count
- 168
- Registration Number
- NCT05846789
- Locations
- 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸IU Health Joe and Shelly Schwarz Cancer Center, Carmel, Indiana, United States
🇺🇸Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome
- Conditions
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 81
- Registration Number
- NCT05845723
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus
- Conditions
- Interventions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 70
- Registration Number
- NCT05835986
- Locations
- 🇹🇭
Ramathibodi Hospital, Mahidol Uni ; Allergy, Immunology & Rheumatology, Dept of Medicine, Bangkok, Thailand
🇩🇪Charité Research Organisation GmbH, Berlin, Germany
🇩🇪Universitätsklinikum Duesseldorf; Klinik fuer Nephrologie und Rheumatologie, Düsseldorf, Germany
A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.
- Conditions
- Interventions
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Australasian Leukaemia and Lymphoma Group
- Target Recruit Count
- 42
- Registration Number
- NCT05833763
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Parkville, Victoria, Australia
🇦🇺Sir Charles Gairdener, Nedlands, Western Australia, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.